Our mission is to reverse the course of serious metabolic diseases and transform patients’ lives. Our dedicated team is laser-focused on reversing the NASH epidemic by restoring the body’s metabolism to a balanced state.
Our multi-modal drug, efruxifermin (EFX), mimics FGF21 to confront the many facets of NASH, and clinical data suggest it has the potential to be a foundational NASH monotherapy.
Results of our BALANCED Phase 2a study showed statistically significant improvement in all key drivers of disease. Patients on EFX experienced reductions in liver fat for all three tested doses of EFX compared to placebo. In addition, in an exploratory analysis after 16 weeks of treatment, 48% of treatment responders who had end-of-treatment biopsies showed at least a one-stage improvement in fibrosis without worsening of NAFLD activity score, 28% achieved at least a two-stage improvement in fibrosis, and 48% achieved NASH resolution without worsening of fibrosis. Patients on drug also experienced improvements in glycemic control, as well as healthier lipid profiles and weight loss.
These results point to the potential for EFX to be a foundational monotherapy for the treatment of NASH.
President & Chief Executive Officer
Chief Operating Officer & Co-Founder
Chief Science Officer & Co-Founder
Chief Financial Officer & Head of Corporate Development
Chief Development Officer
Vice President for Drug Substance Process Development
Vice President, Analytical Development & Quality Control
Vice President, Product & Device Development
Vice President, Finance & Controller
Vice President, Clinical Research & Medical Affairs
We invite qualified applicants who share our commitment to send your resume and cover letter to careers@akerotx.com.
